Each year, this disease affects 2.5 million French people. It concerns 5% of adults, also affects children, and treatments have limits: should we rethink our therapeutic approach to depression?
It is one of the greatest medical problems facing our societies. One in five people have suffered – or will suffer – from depression in their lifetime. And according to the World Health Organization, it will be the second most common disease by 2030. 35% of patients treated show resistance to treatment. Is depression necessarily caused by a chemical imbalance in the brain, namely a lack of serotonin? And what are the other therapeutic avenues?
Treatment of depression: goodbye sadness
We are pleased to receive Raphael Gaillard, director of the hospital-university center of psychiatry at Sainte Anne hospital, professor of psychiatry at the University of Paris-Cité and Bruno Aouizerate, PU-PH, Deputy Director of the Nutrineuro laboratory at the University of Bordeaux, head of department, at the Charles Perrens Hospital Center, head of the Reference Center for anxiety pathologies and depression in Bordeaux.
Today’s report
Meeting with Philippe Domenech psychiatrist, co-director of the Neuromodulation Institute at Sainte Anne Hospital in Paris and Lucie Berkovitch, psychiatrist, researcher in cognitive neuroscience and post-doctoral fellow at Yale University. From vagus nerve stimulation to studies on psychedelic molecules, what combined approaches might be considered to treat resistant depression? Par Antoine Beauchamp :
LA_SCIENCE_CQFD – Report
7 min
Documentary resources
find
le thread of the program of the day on the twitter feed of La Science, CQFD.
Researchers question the role of serotonin in depression (Science & Life, September 2023)
Depression: how does electroconvulsive therapy work? (Inserm, 2018)
The Scientific Method
listen later
listen
58 min
musical references
Headline of the day: slow depression by Arne Vinzon
The opening credits: goca world Par Altin Gun
End credits: Pingpxng by Yin Yin References
